Physician profile
David A Swender
NPI 1306045257
$817.04
in general payments reported to CMS, 2019-2025
15 companies · $47.76 in 2025
The $47.76 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $93.70 · 2022: $52.29 · 2023: $38.92 · 2024: $144 · 2025: $47.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155 · Education: $75.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.48 |
| Education | $75.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $234.57 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $223.57 | 2019-2024 | Fasenra |
| Glaxosmithkline, LLC. | $73.04 | 2019-2022 | |
| Kaleo, INC. | $53.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.28 | 2024-2025 | Eohilia |
| Amgen INC. | $34.00 | 2025 | |
| Optinose US, INC. | $24.97 | 2019 | |
| Shire North American Group INC | $21.18 | 2019 | |
| Genzyme Corporation | $19.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.08 | 2019 | |
| Phadia US INC. | $17.89 | 2020 | |
| Abbott Laboratories | $15.24 | 2020 | |
| Alk-Abello, INC | $14.06 | 2019 | |
| Genentech USA, INC. | $13.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Swender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.